



2024 CLINICAL SCHOLAR AWARD

Introduction: CLL Society is pleased to announce a new funding opportunity for exceptional physician researchers who have already established themselves in the field of CLL and SLL. This Award is designed to support the research efforts of an advanced physician scientist who is engaged in independent clinical research and has demonstrated exceptional leadership, scholarship, and academic success.

Award Amount: CLL Society's 2024 Clinical Scholar Award is for \$300,000 which will be distributed in three annual payments of \$100,000. The first \$100,000 will be paid within 30 days of the effective date, the second \$100,000 will be paid within 30 days after CLL Society's approval of the first submitted annual progress and financial report, and the final \$100,000 will be paid within 30 days after CLL Society's approval of second annual progress and financial report.

Eligibility: Clinical Scholar Award Applicants must be licensed physicians practicing at an accredited academic clinical research institution that is located within the United States for the duration of the award. US citizenship is not required, but the research itself must be conducted in the United States. Applicants should be an independent investigator of at least an assistant professor position or the equivalent. This includes any permanent, independent clinical faculty who are not solely on a laboratory-based tenure-track. Applicants must be able to demonstrate that they have already established themselves as a career physician researcher in the field of CLL and that they possess a broad knowledge of the disease. Applicants should ideally be spending 30% or more of their time on clinical research efforts in their current position, but still have direct patient contact and clinical responsibilities in their role.

Ineligible: Research projects that are to be conducted outside of the United States are not currently eligible. Applicants are ineligible if they are currently receiving funding from any other CLL Society Research Program Grant.

Goal: The Clinical Scholar Award is intended to ultimately advance the development of treatment and/or preventative options that lead to a higher quality of life for those living with CLL and SLL, while continuing to support the careers of established physician scientists.

Study Design: Research proposals should be clinical in nature. Laboratory correlative studies are welcome, but any laboratory studies must directly relate to clinical studies. For this Award, clinical research is defined as patient-oriented research conducted with human subjects or on material of human origin such as tissues, specimens, and cognitive phenomena. Research proposals can include mechanisms of human disease, therapeutic interventions, clinical trials, and the development of new technologies. Emphasis will be placed on the innovation and transformative potential of submitted proposals. Sufficient information must be included in the application to allow CLL Society's Research Review Committee to evaluate the significance, feasibility, and scientific strength of the project. Applicants should demonstrate that their investigative team has the appropriate expertise to complete the proposed research project.



CLL SOCIETY

Projects Considered: Proposals must focus exclusively on research projects directly related to CLL or SLL that will potentially lead to scientific progress.

Budget: Funding should be used to support the Awardee's salary and direct costs (supplies, equipment), with a maximum allowable institutional overhead of 10%. No overhead will be provided for outside institutions. Funding is intended to cover the research rather than administrative costs. We encourage applicants to work with their institutions to reduce administrative costs so that the maximum amount of the award can be used for the research project. Travel expenses are allowed for no more than one hematology/oncology meeting per year. The estimated funding period is July 1, 2024, to June 30, 2027.

Request for Letters of Intent: Applicants should submit their Letter of Intent through [ProposalCentral's application portal](#) **no later than November 6th, 2023 at 11:59 PM EST**. Letters of Intent will not be received after this date/time. Applicants will be notified via email whether to then submit their full research proposals by **December 4th, 2023**.

Request for Full Research Proposals: Full proposal submissions are by invitation only, after review and approval of the Letter of Intent. Those approved will be invited via email to submit their full research proposal through [ProposalCentral's application portal](#). The deadline for submission is **no later than January 12th, 2024, at 11:59 PM EST**. Any applications received after this date/time will not be considered. Incomplete applications will also not be considered.

Required Documents: Please read through the [Application Instructions](#) and [Program Guidelines](#) in full prior to beginning the application process.

Selection Process: Full research proposals will undergo a formal peer-review process by CLL Society's Research Review Committee and will be critiqued and ranked for funding priority based on strategic and scientific merit. Applicants will be notified of the status of their application no later than **May 3rd at 11:59 PM EST**. Written critiques will be available to the applicants who were invited to submit a full research proposal. In submitting a full proposal, researchers agree to allow CLL Society's Research Review Committee to access your full application materials.